177 related articles for article (PubMed ID: 25681878)
1. The usefulness of 18F-FDG-PET/CT in discriminating benign from malignant ovarian teratomas.
Yokoyama T; Takehara K; Yamamoto Y; Okame S; Shiroyama Y; Yokoyama T; Nogawa T; Sugawara Y
Int J Clin Oncol; 2015 Oct; 20(5):960-6. PubMed ID: 25681878
[TBL] [Abstract][Full Text] [Related]
2. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
[TBL] [Abstract][Full Text] [Related]
3. The additional value of attenuation correction CT acquired during 18F-FDG PET/CT in differentiating mature from immature teratomas.
Cho A; Kim SW; Choi J; Kang W; Lee JD; Yun M
Clin Nucl Med; 2014 Mar; 39(3):e193-6. PubMed ID: 23989446
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of preoperative SUVmax on FDG-PET/CT for the detection of ovarian cancer.
Tanizaki Y; Kobayashi A; Shiro M; Ota N; Takano R; Mabuchi Y; Yagi S; Minami S; Terada M; Ino K
Int J Gynecol Cancer; 2014 Mar; 24(3):454-60. PubMed ID: 24463640
[TBL] [Abstract][Full Text] [Related]
5. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
6. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC
Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology.
Castellucci P; Perrone AM; Picchio M; Ghi T; Farsad M; Nanni C; Messa C; Meriggiola MC; Pelusi G; Al-Nahhas A; Rubello D; Fazio F; Fanti S
Nucl Med Commun; 2007 Aug; 28(8):589-95. PubMed ID: 17625380
[TBL] [Abstract][Full Text] [Related]
9. The performance of contrast-enhanced FDG PET/CT for the differential diagnosis of unexpected ovarian mass lesions in patients with nongynecologic cancer.
Lee JW; Lee JH; Cho A; Yun M; Lee JD; Kim YT; Kang WJ
Clin Nucl Med; 2015 Feb; 40(2):97-102. PubMed ID: 25546187
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of metabolic tumor volume assessed by 18F-FDG PET/CT added to SUVmax for characterization of thyroid 18F-FDG incidentaloma.
Kim BH; Kim SJ; Kim H; Jeon YK; Kim SS; Kim IJ; Kim YK
Nucl Med Commun; 2013 Sep; 34(9):868-76. PubMed ID: 23797273
[TBL] [Abstract][Full Text] [Related]
11. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results.
Naswa N; Sharma P; Soundararajan R; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Diagn Interv Radiol; 2013; 19(4):294-8. PubMed ID: 23439252
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET-CT and USG/CT in benign and malignant ovarian tumors with postoperative histopathological correlation.
Kuyumcuoğlu U; Guzel AI; Celik Y; Erdemoğlu M; Komek H
Ginekol Pol; 2011 Aug; 82(8):602-6. PubMed ID: 21957605
[TBL] [Abstract][Full Text] [Related]
13. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
[TBL] [Abstract][Full Text] [Related]
14. SUVmax of 18F-FDG PET/CT in the differential diagnosis of benign and malignant thyroid nodules according to tumor volume.
Kim TH; Ji YB; Song CM; Kim JY; Choi YY; Park JS; Tae K
World J Surg Oncol; 2015 Jul; 13():217. PubMed ID: 26179774
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET/CT to predict optimal primary cytoreductive surgery in patients with advanced ovarian cancer: preliminary results.
Alessi A; Martinelli F; Padovano B; Serafini G; Lorusso D; Lorenzoni A; Ditto A; Lecce F; Mira M; Donfrancesco C; Raspagliesi F; Crippa F
Tumori; 2016; 102(1):103-7. PubMed ID: 26350201
[TBL] [Abstract][Full Text] [Related]
16. Current generation time-of-flight (18)F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands.
Koopman D; van Dalen JA; Stigt JA; Slump CH; Knollema S; Jager PL
Ann Nucl Med; 2016 Feb; 30(2):145-52. PubMed ID: 26644009
[TBL] [Abstract][Full Text] [Related]
17. Localization and prediction of malignant potential in recurrent pheochromocytoma/paraganglioma (PCC/PGL) using 18F-FDG PET/CT.
Fikri AS; Kroiss A; Ahmad AZ; Zanariah H; Lau WF; Uprimny C; Donnemiller E; Kendler D; Nordin AJ; Virgolini IJ
Acta Radiol; 2014 Jun; 55(5):631-40. PubMed ID: 24037430
[TBL] [Abstract][Full Text] [Related]
18. Assessment of ovarian teratoma and lymphadenopathy by 18F-FDG PET/CT.
Balink H; Apperloo MJ; Collins J
Clin Nucl Med; 2012 Aug; 37(8):804-6. PubMed ID: 22785518
[TBL] [Abstract][Full Text] [Related]
19. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
20. Analysis of positron emission tomography/computed tomography in patients to differentiate between malignant transformation of endometrioma and endometrioma.
Kusunoki S; Ota T; Kaneda H; Kimura M; Terao Y; Takeda S
Int J Clin Oncol; 2016 Dec; 21(6):1136-1141. PubMed ID: 27380167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
